Payment overview · 2025
General Payments
$1,423.88
71 reported records · 25 companies
Healthcare provider profile · identity verified
Anil R Modi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAGRANGE, GA · NPI 1508868704
Verified facts
What the public records show
CMS Open Payments records show Anil R Modi, MD received $1,423.88 in general payments during 2025 across 71 reported records.
SHIELD THERAPEUTICS INC accounted for 8.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $114.37 | 8.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $101.58 | 7.1% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $98.51 | 6.9% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $94.89 | 6.7% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $82.53 | 5.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.00 | 5.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.32 | 5.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.35 | 5.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.11 | 5.2% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $72.44 | 5.1% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $71.55 | 5.0% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $70.45 | 5.0% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $63.49 | 4.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.76 | 4.3% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $52.44 | 3.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.60 | 2.8% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $28.78 | 2.0% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$27.45 | 1.9% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $25.42 | 1.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.27 | 1.5% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $18.58 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.49 | 1.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.80 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.17 | 1.2% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $14.53 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,423.88 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $114.37 | 5 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $101.58 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $98.51 | 5 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $82.53 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $81.00 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $81.00 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $78.32 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.35 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.35 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $72.44 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $71.55 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $71.53 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $70.45 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $63.49 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.76 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.27 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.27 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.68 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $52.44 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $52.15 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 203 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 89 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
203 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 937 | 204 |
| Atorvastatin Calcium | Atorvastatin Calcium | 779 | 206 |
| Levothyroxine Sodium | Levothyroxine Sodium | 657 | 139 |
| Omeprazole | Omeprazole | 567 | 120 |
| Metoprolol Tartrate | Metoprolol Tartrate | 566 | 105 |
| Gabapentin | Gabapentin | 530 | 126 |
| Metformin Hcl | Metformin Hcl | 492 | 115 |
| Lisinopril | Lisinopril | 489 | 96 |
| Losartan Potassium | Losartan Potassium | 405 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 364 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 360 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 349 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 324 | 87 |
| Furosemide | Furosemide | 314 | 78 |
| Zolpidem Tartrate | Zolpidem Tartrate | 300 | 45 |
| Memantine Hcl | Memantine Hcl | 260 | 21 |
| Trazodone Hcl | Trazodone Hcl | 249 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 236 | 68 |
| Allopurinol | Allopurinol | 226 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 226 | 46 |
| Montelukast Sodium | Montelukast Sodium | 226 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 214 | 23 |
| Famotidine | Famotidine | 206 | 48 |
| Simvastatin | Simvastatin | 204 | 55 |
| Eliquis | Apixaban | 203 | 35 |
| Nifedipine Er | Nifedipine | 198 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 194 | suppressed |
| Potassium Chloride | Potassium Chloride | 193 | 42 |
| Glipizide Er | Glipizide | 192 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 187 | 40 |
| Donepezil Hcl | Donepezil Hcl | 172 | 20 |
| Celecoxib | Celecoxib | 159 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 44 |
| Azithromycin | Azithromycin | 154 | 124 |
| Carvedilol | Carvedilol | 144 | 35 |
| Benazepril Hcl | Benazepril Hcl | 140 | 35 |
| Tramadol Hcl | Tramadol Hcl | 139 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 42 |
| Alprazolam | Alprazolam | 114 | 29 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 114 | 15 |
| Fenofibrate | Fenofibrate | 108 | 32 |
| Clonidine Hcl | Clonidine Hcl | 99 | 44 |
| Sertraline Hcl | Sertraline Hcl | 99 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 36 |
| Glipizide | Glipizide | 95 | 12 |
| Alendronate Sodium | Alendronate Sodium | 92 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 48 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 90 | 35 |
| Farxiga | Dapagliflozin Propanediol | 89 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 24 |
| Bupropion Xl | Bupropion Hcl | 77 | 19 |
| Levetiracetam | Levetiracetam | 76 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 69 | suppressed |
| Jardiance | Empagliflozin | 68 | 15 |
| Meloxicam | Meloxicam | 68 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | suppressed |
| Finasteride | Finasteride | 65 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 62 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 55 |
| Atenolol | Atenolol | 62 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 43 |
| Pregabalin | Pregabalin | 57 | 13 |
| Ezetimibe | Ezetimibe | 56 | 13 |
| Sucralfate | Sucralfate | 56 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 16 |
| Topiramate | Topiramate | 55 | suppressed |
| Nabumetone | Nabumetone | 52 | suppressed |
| Roflumilast | Roflumilast | 52 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 51 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 49 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 48 | suppressed |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 17 |
| Ozempic | Semaglutide | 43 | suppressed |
| Cephalexin | Cephalexin | 42 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 39 |
| Levofloxacin | Levofloxacin | 39 | 30 |
| Valsartan | Valsartan | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | 11 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Prednisone | Prednisone | 26 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Felodipine Er | Felodipine | 20 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 20 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,423.88 · 71 records | SHIELD THERAPEUTICS INC | ACCRUFER, AUSTEDO XR, AVONEX, CREXONT, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Gamunex-C, HYQVIA, Hizentra, INGREZZA, JARDIANCE, KISUNLA, Kerendia, Leqembi, NURTEC ODT, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, Sunosi, TRINTELLIX, TYSABRI, UBRELVY, VRAYLAR, VUMERITY, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZTLido | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error